– USA, CA – Ambrx Biopharma Inc. (NYSE: AMAM), a clinical-stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics, today announced the appointment of Paul Maier to its Board of Directors.
Paul Maier will also join the Audit Committee as Chair.
“I am thrilled to welcome Paul to our Board and look forward to having him serve as the Chair of our Audit Committee moving forward. Paul is a distinguished executive whose financial pedigree and strategic experience will benefit Ambrx as we grow the company and progress our clinical candidates through their next stages of development,” said Chairman and CEO, Dr. Feng Tian.
About Paul V. Maier
Paul Maier is a seasoned executive with extensive senior operational, international, and financial management experience, including 25 years in rapid growth pharmaceutical and biotechnology companies. Mr. Maier currently serves on the Board of Directors for Small Pharma Inc., 4D Pharma PLC, Eton Pharmaceuticals, and International Stem Cell Corporation. Most recently, Mr. Maier was CFO of Sequenom, Inc., from 2009 until 2014. Before Sequenom, Mr. Maier spent 15 years at Ligand Pharmaceuticals where he served as SVP, CFO. Early in his career, Mr. Maier held various financial executive roles at companies such as DFS West and ICN Pharmaceuticals, Inc., and several other private companies.
“I am excited by the potential of Ambrx’s engineered precision biologics and robust antibody drug candidates, as well as the company’s leadership team and development plans,” said Paul Maier. “I want to thank Tian and the Ambrx team for the opportunity to serve on the company’s Board and look forward to advising the company in the months and years ahead as we seek to create value for stakeholders and better treatment outcomes for patients.”
Mr. Maier received his BS in Business Logistics from Pennsylvania State University and received his MBA from Harvard Graduate School of Business.
About Ambrx Biopharma Inc.
Ambrx is a clinical-stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics. These include next-generation antibody-drug conjugates, bispecific, targeted immuno-oncology therapies, novel cytokines to modulate the immune system, and long-acting therapeutic peptides for metabolic and cardiovascular disease. Ambrx is advancing a robust portfolio of clinical and preclinical programs designed to optimize efficacy, safety, and ease of use, in multiple therapeutic areas, including its lead product candidate ARX788. In addition, Ambrx has clinical collaborations with multiple partners, for drug candidates generated using Ambrx technology.
For more information: https://ambrx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
